Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Type-specific Serologic Testing for Herpes Simplex Virus-2.

Peter Leone1

  • 1University of North Carolina, Department of Infectious Diseases, CB # 7030, 547 Burnett - Womac IC, Chapel Hill, NC 27599-7030, USA. pal007@med.unc.edu

Current Infectious Disease Reports
|March 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.

The Journal of infectious diseases·2025
Same author

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2022
Same author

Rate of Decline in Nontreponemal Antibody Titers and Seroreversion After Treatment of Early Syphilis.

Sexually transmitted diseases·2016
Same author

Previously undiagnosed HIV infections identified through cluster investigation, North Carolina, 2002-2007.

AIDS and behavior·2014
Same author

"No one's at home and they won't pick up the phone": using the Internet and text messaging to enhance partner services in North Carolina.

Sexually transmitted diseases·2014
Same author

Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2012

Genital herpes affects millions of US adults, with most unaware of their infection. Type-specific tests can identify individuals, enabling interventions to reduce herpes simplex virus-2 (HSV-2) transmission.

Area of Science:

  • Infectious Diseases
  • Epidemiology
  • Public Health

Background:

  • Genital herpes, caused by herpes simplex virus-2 (HSV-2), is highly prevalent in the United States, affecting an estimated 60 million adults.
  • The majority of infected individuals (over 90%) are asymptomatic and unaware of their condition, contributing to ongoing transmission.
  • The silent nature of genital herpes fuels its continued increase in prevalence.

Purpose of the Study:

  • To highlight the public health challenge posed by asymptomatic HSV-2 infections.
  • To emphasize the importance of newly available type-specific serologic tests for HSV-1 and HSV-2 differentiation.
  • To advocate for screening of at-risk populations to facilitate early identification and intervention.

Main Methods:

  • Utilizes existing epidemiological data on HSV-2 prevalence in the US.

Related Experiment Videos

  • References the development and availability of type-specific serologic diagnostic tests.
  • Proposes a public health strategy involving screening and counseling.

    • Main Results:

    • Accurate differentiation between HSV-1 and HSV-2 infections is now possible with type-specific serologic tests.
    • Screening at-risk populations can identify individuals with genital herpes.
    • Identification provides opportunities for risk-reduction counseling and transmission interventions.

    Conclusions:

    • Early identification of genital herpes through screening is crucial for managing the silent epidemic of HSV-2.
    • Type-specific serologic testing is a key tool for differentiating HSV types and informing patient care.
    • Interventions and counseling for identified individuals can significantly reduce HSV transmission rates.